Citation

Kelly DL, Gorelick DA, Wehring HJ, Vyas G, Buchanan RW. Ann. Intern Med. 2020; 172(2): 167-168.

Affiliation

University of Maryland School of Medicine, Baltimore, Maryland (D.L.K., D.A.G., H.J.W., G.V., R.W.B.).

Copyright

(Copyright © 2020, American College of Physicians)

DOI

10.7326/L19-0706

PMID

31958830

Abstract

D'Anci and colleagues' systematic review (1) is a welcome addition to the literature on the prevention and treatment of suicidality, a major public health crisis in the United States. However, their criterion of including only double-blind, randomized clinical trials caused them to omit mention of clozapine, one of the few medications with proven efficacy for the treatment of suicidality.

Clozapine, an antipsychotic medication, was approved by the U.S. Food and Drug Administration (FDA) for the indication of reducing the risk for recurrent suicidal behavior in persons with schizophrenia or schizoaffective disorder. This approval was based...

Language: en